Tag: dose limiting toxicity

1. Semaglutide 2.4 mg combined with once weekly cagrilintide therapy was not associated with increase in adverse events compared to semaglutide alone. 2. Compared to control, combined cagrilintide and semaglutide improved glycemic parameters and mean body weight reduction at 20 weeks. Evidence Rating Level: 1 (Excellent)  Study Rundown: Semaglutide is a glucagon-like...